Epidermolysis Bullosa Market Growth Accelerated by Gene Therapy Advances

 

Epidermolysis bullosa (EB) is a group of rare genetic conditions that cause easy blistering of the skin and mucous membranes. EB therapies aim to treat the symptoms and heal wounds through dressing, medication and gene therapy approaches. The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Gene therapy is one of the major trends driving growth in the EB market. Gene therapy aims to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. Numerous gene therapy techniques are being researched for EB including gene supplementation therapy, gene editing, and cell therapies. Advancements in viral and non-viral gene delivery systems are accelerating clinical research of EB gene therapies. For example, Amryt Pharma and other players are developing precision gene therapy approaches to permanently correct the genetic defects that cause EB. Rising R&D investments and improving gene therapy tools are expected to boost the clinical adoption of these therapies over the forecast period.

Segment Analysis
The global epidermolysis bullosa market is segmented based on type, therapy, and end-user. By type, the dystrophic epidermolysis bullosa segment currently dominates the market due to the high prevalence of dystrophic epidermolysis bullosa. By therapy, the surgical treatment segment leads the market as it provides wound care management and protects blistering areas. By end-user, hospitals accounted for the largest share as severe EB patients require long-term hospitalization and access to specialized staff and equipment.

Key Takeaways

The global epidermolysis bullosa market is expected to witness high growth in the forecast period from 2023 to 2030.

Regional analysis North America region is expected to witness the fastest growth during the forecast period. This is attributed to the higher adoption of advanced therapies, growing research on epidermolysis bullosa treatment, and strong presence of key players.

Key players related content- Key players operating in the epidermolysis bullosa market include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi.

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more